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Closed-form REML estimators and sample size
determination for mixed effects models for
repeated measures under monotone missingness
Yongqiang Tang
We derive the closed-form restricted maximum likelihood (REML) estimator and Kenward-Roger’s variance
estimator for fixed effects in the mixed effects model for repeated measures (MMRM) when the missing data
pattern is monotone. As an important application of the analytic result, we present the formula for calculating
the power of treatment comparison using the Wald t test with the Kenward-Roger adjusted variance estimate
in MMRM. It allows adjustment for baseline covariates without the need to specify the covariate distribution in
randomized trials. A simple two-step procedure is proposed to determine the sample size needed to achieve the
targeted power. The proposed method performs well for both normal and moderately nonnormal data even in
small samples (n = 20) in simulations. An anti-depressant trial is analyzed for illustrative purposes. Copyright c©
2015 John Wiley & Sons, Ltd.
Keywords: Kenward-Roger’s variance estimator; Power and sample size; Restricted maximum likelihood
1. Introduction
In clinical trials, the mixed effects model for repeated measures (MMRM) is commonly used to analyze longitudinal
continuous outcomes collected at a number of fixed time points [1, 2, 3]. In MMRM, there is no random effect, and the
within-subject dependence is modeled by an unstructured covariance matrix. It assumes that the post-baseline outcome
yi = (yi1, . . . , yip)
′ follows a p-dimensional multivariate normal distribution
yi ∼ Np[(α′1xi, . . . ,α′pxi)′,Σ], (1)
where xi is the baseline covariate (including intercept and treatment status) for subject i, and αj is the q × 1 vector
of covariate and treatment effects at visit j. In clinical trials, the primary analysis model is generally pre-specified in the
protocol. While it is difficult, if not impossible, to correctly pre-specify the covariance structure, the use of an unstructured
covariance matrix usually provides reasonable control of the type I error rate [1]. Any stronger assumptions on the mean
response or covariance structure can be difficult to be accepted by regulatory agencies without rigid justifications.
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Some theories for model (1) can be presented in a simple and elegant way [4] for monotone missing data. Closed-
form maximum likelihood (ML) estimators [5] and Bayes estimators [6] can be obtained by factoring the observed data
distribution as f(yi1, . . . , yij) = f(yi1)
∏j
k=2 f(yik|yi1, . . . , yik−1). These analytic results are of great practical interest
since the real clinical data are often monotone or approximately monotone. For near-monotone data, monotone pattern
can be obtained by removing subjects with intermittent missing data [7], by ignoring data collected after the first missing
visit, or by filling in the intermittent missing data using a single imputation method. A numerical example is provided
in Section 2.4. Alternatively, the intermittent missing data can be handled using the monotone expectation-maximization
(MEM) algorithm [8] or monotone data augmentation (MDA) algorithm [6, 9] whenever appropriate.
In Section 2, we derive the closed-form restricted maximum likelihood (REML) estimator and assess the biases of
ML and REML estimators for model (1) under monotone missingness. We obtain the closed-form Kenward-Roger (KR)
adjusted variance estimator [10] and compare it with the delta variance for inference on fixed effects. An anti-depressant
trial [11] is analyzed for illustrative purposes.
Sample size calculation is critical in planning a clinical trial. If the sample size is too small, the trial may have little
chance to detect a clinically meaningful treatment effect, whereas an unnecessarily large sample may waste time, money
and resources. Sample size determination methods were previously developed for MMRM [3, 12] based on the asymptotic
variance of the treatment effect and/or normal approximation. Since the use of the asymptotic variance underestimates the
true variance of the estimated treatment effect [10], and the normal distribution can not adequately approximate the t
distribution, the methods in [3, 12] tend to underestimate the required size especially in small samples.
In Section 3, we derive the power formula for the KR adjusted Wald t test comparing two treatments in MMRM. The
power is computed based on the KR adjusted variance and t test. Therefore, the proposed method tends to be more accurate
than the methods of [3, 12], but the corresponding formulae have simpler expressions. One advantage of our method is
that it allows adjustment for covariates, but there is no need to specify the covariate distribution. Information about the
covariate distribution is usually not available at the design stage since subjects will be enrolled into the trials only if they
meet certain inclusion/exclusion criteria. There is no closed-form solution for the sample size needed to achieve a targeted
power. We propose a two-step procedure to approximate the required size and assess its performance for both normal and
non-normal continuous data in small to moderate samples via simulation.
We focus on the monotone missing data. Section 5 will discuss how to apply the sample size calculation method to
non-monotone missing data.
2. REML estimator under monotone missingness
2.1. Closed-form REML estimator
We assume the missing data pattern is monotone in the sense that if yij is observed, then yit’s are observed for all t ≤ j.
Let ri denote the dropout pattern according to the last observation. A subject is in pattern ri = s if yij is observed for
j ≤ s, ri = 0 if yi is missing, and ri = p if the subject completes all p visits. Without loss of generality, we sort the data
so that subjects in pattern s are before subjects in pattern t if s > t. For notational simplicity, we assume there are two
treatment groups (gi = 1 for active treatment, gi = 0 for placebo). Let Bgs denote the subset of subjects retained at visit s
(yis is observed) in group g, ngs the number of subjects in Bgs, and ns =∑1g=0 ngs. Let xbi denote the baseline covariates
excluding the intercept term and gi. The baseline outcome yi0 is usually included as a covariate in xbi. Let x¯gs be the
average of xbi among subjects in Bgs.
The clinical data are often analyzed by model (1), where xi = (1,x′bi, gi)′ and αj = (µj ,α′jb, τj)′. The ML estimator
of the variance parameters is biased downward since it does not take into account of the loss in degrees of freedom
(d.f.) from the estimation of αj’s [13]. The REML procedure is generally employed to reduce the bias in estimating
the variance parameters, and inference for fixed effects is often made based on the KR variance estimate especially in
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small samples. Let Wij be a pq × 1 vector whose [(j − 1)q + 1]-th through [jq]-th entries are given by xi while other
entries are 0’s. Let Wi = (Wi1, . . . ,Wiri)′ and yio = (yi1, . . . , yiri)′. Let W = (W ′1, . . . ,W ′n)′ and Y = (y′1o, . . . ,y′no)′.
The restricted likelihood is the marginal likelihood of KY , where N =
∑n
i=1 ri and K is any (N − pq)×N matrix of
full rank satisfying KW = 0. The restricted log-likelihood ℓr does not depend on α and the choice of K , and can be
expressed as [14, 15]
2ℓr =−
n∑
i=1
log |Σri | − log |
n∑
i=1
W ′iΣ
−1
ri Wi| −
[
n∑
i=1
y′ioΣ
−1
ri yio
−(
n∑
i=1
y′ioΣ
−1
ri Wi)(
n∑
i=1
W ′iΣ
−1
ri Wi)
−1(
n∑
i=1
W ′iΣ
−1
ri yio)
]
,
(2)
where Σk is the leading k × k submatrix of Σ.
Let Σ = LΛL′ be the LDL decomposition of Σ, where U =

1 0 . . . 0
−β21 1 . . . 0
. . . . . . 0
−βp1 . . . −βp,p−1 1
, L = U−1 and Λ =
diag(σ21 , . . . , σ2p). Let ljt be the (j, t) entry of L. The decomposition admits nice interpretation. The entries βj =
(βj1, . . . , βjj−1)
′ are the regression parameters of yij on ~yj−1 = (yi1, . . . , yi,j−1)′ since model (1) can be written as
(y
i1
, . . . , y
ip
)′ ∼ Np[(α′1xi, . . . ,α′pxi)′,Λ], (3)
which can be reorganized as [9]
yij = x
′
iαj + ~y
′
ij−1βj + εij = z
′
i,j−1θj + εij for j ≤ p, (4)
where y
ij
= yij −
∑j−1
t=1 βjtyit, αj = αj −
∑j−1
t=1 βjtαt, θj = (α
′
j ,β
′
j)
′
, zij = (x
′
i, ~y
′
ij)
′
, εij ∼ N(0, σ2j ), and εij’s are
independent.
Let Xoj = [x1, . . . ,xnj ]′, Zoj = [z1j , . . . , znjj ]′, and Yoj = (y1j , . . . , ynjj)′. The least square (LS) estimator for the
parameters in model (4) is
θˆj = (Z
′
ojZoj )
−1Z ′ojYoj and σˆ
2
j = Sˆj/(nj − q − j + 1),
where Sˆj =
∑nj
i=1(yij − z′ij−1θˆj)2. The ML estimator for the parameters in model (4) is given by
θˆj,ml = θˆj and σˆ2j,ml = Sˆj/nj.
Lemma 1 derives the closed-form REML estimator for the parameters in model (1). Its proof is given in the appendix.
Lemma 1 (a) The asymptotic variance of the fixed effect estimate (αˆ′1, . . . , αˆ′p)′ is (
∑n
i=1W
′
iΣ
−1
ri Wi)
−1 = (L⊗
Iq)Vw(L
′ ⊗ Iq), where Iq is the q × q identity matrix, and Vw = diag[σ21(X ′o1Xo1)−1, . . . , σ2p(X ′opXop)−1].
(b) The restricted log-likelihood (2) can be decomposed as the sum of p independent log-likelihoods ℓr =
∑p
j=1 ℓrj +
constant, where
ℓrj =
q − nj
2
log(σ2j )−
(Yoj − ~Yojβj)′Qj(Yoj − ~Yojβj)
2σ2j
, (5)
Qj = I −Xoj (X ′ojXoj)−1Xoj , and ~Yoj is a nj × (j − 1) matrix whose (i, t) entry is yit.
(c) The REML estimator is βˆj = (~Y ′ojQj ~Yoj )−1~Y ′ojQjYoj , αˆj = (X ′ojXoj)−1X ′oj (Yoj − ~Yoj βˆj) and σˆ2j,re = Sˆj/(nj − q).
Furthermore, θˆj,re = (αˆ′j , βˆ′j)′ = θˆj .
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(d) The asymptotic variance of βˆj based on the observed or expected information matrix is given respectively by
var
O
(βˆj) = σ
2
j (
~Y ′ojQj
~Yoj )
−1 and var
E
(βˆj) = σ
2
j [E(~Y ′ojQj ~Yoj )]
−1 =
σ2j
nj − qΣ
−1
j−1.
Remarks:
1) Lemma 1(a) is also valid for models with structured covariance matrix;
2) We set ~Yojβj = 0 at j = 1 since βj (~Yoj ) is an empty vector (matrix);
3) (~Y ′ojQj ~Yoj )−1 is identical to the lower-right (j − 1)× (j − 1) submatrix of (Z ′ojZoj)−1.
Lemma 1(b) can also be derived from the Bayesian viewpoint based on the fact [14] that the restricted likelihood is
proportional to the marginal posterior density over the variance parameters under a flat prior for (α,Σ). We have to ignore
the Jacobian correction factor in the posterior density under reparameterization since the REML estimators are invariant
under reparameterization. Under a flat prior, (θj , σ2j )’s are independent in the posterior distribution, and the posterior
density of (θj , σ2j ) is proportional to the likelihood function for model (4), which implies that
σ2j |Y ∼ Sˆj/χ2nj−q−j−1,
βj |σ2j , Y ∼ Nj−1(βˆj , σ2j [~Y ′ojQj ~Yoj ]−1),
αj |σ2j ,βj , Y ∼ Nq[(X ′ojXoj )−1X ′oj (Yoj − ~Yojβj), σ2j (X ′ojXoj)−1].
The marginal posterior distribution of (βj , σ2j ) is given by
f(σ2j ,βj |Y ) = f(σ2j |Y )f(βj |σ2j , Y ) ∝ exp(ℓrj ).
2.2. Bias in parameter estimates
The LS, ML and REML methods produce identical estimate of θj’s. Since θˆj is an unbiased estimate of θj , it is
easy to show by induction that (lˆj1, . . . , lˆjj) and αˆj =
∑j
t=1 lˆjtαˆt are unbiased respectively for (lj1, . . . , ljj) and
αj =
∑j
t=1 ljtαt.
For σ2j , the LS estimator is unbiased. The bias E(σˆ2j,re)− σ2j = −(j − 1)σ2j /(nj − q) of the REML estimator is smaller
than that E(σˆ2j,ml)− σ2j = −(q + j − 1)σ2j /nj of the ML estimator.
The bias is not invariant to reparameterization. In REML, the bias in Σˆ = LˆΛˆLˆ′ is of the order of O(n−2). It can be
derived by the Cox-Snell [16] method (using the equation on line 21, page 2586 of [17] and equation (9.62) of [18]), or
based on the second-order Taylor series expansion of Σˆ− Σ = LˆΛˆLˆ′ − LΛL′ around (βj , σ2j )’s. In ML, the bias in ΣˆML
is O(n−1) since E(Σˆre − ΣˆML) = E[Lˆ diag(ϕ1, . . . , ϕp)Lˆ′], where ϕj = E(σˆ2j,re − σˆ2j,ml) = O(n−1). The bias in the LS
estimator of Σ is also O(n−1).
2.3. Variance of fixed effects
The fixed effect estimate is αˆ = (αˆ1, . . . , αˆp)′ = Lˆ(αˆ1, . . . , αˆp)′, where αˆj is defined in Lemma 1c. The asymptotic
variance of αˆ given in Lemma 1a is in fact the variance of the estimate (α˜′1, . . . , α˜′p)′ assuming that the variance parameters
(βj , σ
2
j )’s and hence L are known, where (α˜1, . . . , α˜p)′ = L(α˜1, . . . , α˜p)′, α˜j = (X ′ojXoj )−1X ′oj (Yoj − ~Yojβj), and
var(α˜j) = σ
2
j (X
′
ojXoj )
−1
. Let Φp = var(α˜p) =
∑p
j=1 l
2
pjσ
2
j (X
′
ojXoj )
−1
.
In the appendix, we show cov(αˆp − α˜p, α˜p) = 0, and derive the variance of αˆp − α˜p
Ψp = var(αˆp − α˜p) =
p∑
j=2
l2pj(Vdj + Vej) ≈
p∑
j=2
l2pjVdj , (6)
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where Lj is the leading j × j submatrix of L, (ωj1, . . . , ωj,j−1) are the diagonal elements of L′j−1var(βˆj)Lj−1 for j ≥ 2,
Djt = (X
′
ojXoj)
−1 − (X ′otXot)−1, Vdj =
∑j−1
t=1 ωjtσ
2
tDjt, Ve1 = 0, Vej =
∑j−1
t=1 ωjt(Vdt + Vet) at j ≥ 2, Vej is of lower
order than Vdj and can be ignored. Thus
var(αˆp) = Φp +Ψp =
p∑
j=1
l2pjσ
2
j (X
′
ojXoj)
−1 +
p∑
j=2
l2pjVdj. (7)
Although Ψp is of lower order than Φp, it is not negligible in small samples. The variance at other visits can be derived
similarly, and would not be presented here.
Let ∆s = x¯1s − x¯0s, Sxs =
∑1
g=0
∑
i∈Bgs
(xbi − x¯gs)⊗2 and Vxs = n−11s + n−10s +∆′sS−1xs ∆s, where a⊗2 = aa′. By
equation (7), the variance of the treatment effect estimate τˆp is given by
var(τˆp) =
p∑
j=1
l2pjσ
2
jVxj +
p∑
j=2
l2pj
j−1∑
t=1
ωjtσ
2
t (Vxj − Vxt). (8)
2.3.1. Kenward-Roger (KR) variance estimate The KR variance estimate has been widely used in practice particularly
when the sample size is small. The KR approach not only takes into account of the variability in the variance parameter
estimate, but also adjusts for the bias in Φˆp. In the appendix, we show the bias in Φˆp is
Ψ∗p = E(Φˆp)− Φp =
p∑
j=2
j−1∑
t=1
l2pjωjtσ
2
t (X
′
otXot)
−1 −
p∑
j=2
j − 1
nj − q σ
2
j l
2
pj(X
′
ojXoj )
−1. (9)
If var
E
(βˆj) in Lemma 1d is used, then ωjtσ2t = σ2j /(nj − q), Ψp =
∑p
j=2 l
2
pjσ
2
j [
∑j−1
t=1 Djt]/(nj − q), and Ψ∗p = −Ψp.
The KR variance evaluated at the REML estimator is given by
v̂arkr(αˆp) = Φˆp + Ψˆp − Ψˆ∗p = Φˆp + 2Ψˆp, (10)
and it provides a roughly unbiased estimate of the variance Φp +Ψp of αˆp while the lower order terms are dropped.
The KR variance estimate is invariant under reparameterization of an unstructured covariance matrix [17]. Although the
derivation of the KR variance estimate relies on var
E
(βˆj), equation (10) yields the same result as Kenward-Roger’s [10]
formula if the calculation is based on var
O
(βˆj).
2.3.2. Delta variance estimate An alternative variance estimate for αˆp can be obtained from the delta method
Vd =
p∑
j=1
∂αp
∂θj
var(θˆj)(
∂αp
∂θj
)′ =
p∑
j=1
l2pjσ
2
j α¨j(Z
′
ojZoj )
−1α¨′j ,
where ∂αp/∂θj = lpjα¨j and α¨j = (Iq ,α1, . . . ,αj−1).
By equation (19) in the appendix, the delta variance evaluated at the LS estimator can be written as
Vˆd =
p∑
j=1
lˆ2pj σˆ
2
j (X
′
ojXoj )
−1 +
p∑
j=2
lˆ2pj(~ˆαj − ~ˆα∗j )Vβj (~ˆαj − ~ˆα∗j )′,
where ~ˆαj = (αˆ1, . . . , αˆj−1) and ~ˆα∗j = (X ′ojXoj )−1X ′oj ~Yoj . The delta variance estimate tends to be more conservative
than the KR variance estimate since the latter is a roughly unbiased variance estimate for αˆp, while the former
Statist. Med. 2015, 00 1–14 Copyright c© 2015 John Wiley & Sons, Ltd. www.sim.org 5
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Table 1: Treatment effect estimate and its standard error at week 6 in an antidepressant trial
Treatment Standard Error
Method effect Asymptotic KR Delta
MMRM −2.799 1.114 1.116 1.122
cLDA −2.799 1.098 1.108 -
overestimates the variance of αˆp by
E(Vˆd)− Φp −Ψp ≈
p∑
j=1
var(lˆpj)σ
2
j (X
′
ojXoj )
−1 +
p∑
j=2
var(lˆpj)[
j−1∑
t=1
Djtωjtσ
2
t ].
The delta variance is closely related to the variance from the multiple imputation (MI) inference [19]. One may compare
the KR variance estimate given in equation (10) with the MI variance derived by [19]. In general, the MI inference tends
to be slightly more conservative than the REML inference [2].
2.4. Analysis of an antidepressant trial
To illustrate the analytic result derived in this section, we analyze an antidepressant trial reported by [11]. The Hamilton
17-item rating scale for depression (HAMD17) is collected at baseline and weeks 1, 2, 4, 6. The dataset consists of 84
subjects on the active treatment, and 88 subjects on placebo. The number of subjects in patterns 0 to 4 is respectively
(0, 7, 5, 11, 65) in the placebo arm, and (0, 6, 5, 9, 64) in the active arm. The missing data are mainly due to dropout. Only
one subject has an intermittent missing value at visit 2. We impute the intermittent missing value as 11.70432 based on
the linear regression of yi2 on (yi0, yi1, gi), where yi0 is the baseline HAMD17. A better approach would be to replace the
missing value with multiple plausible values to reflect uncertainty about the missing data via the MI procedure [20, 9].
However, due to the small amount of non-monotone missing data, the result from this single imputation approach is very
close to that from the MI inference [20].
Table 1 reports the result from the MMRM analysis. The model includes visit, baseline × visit and treatment × visit
interactions as the fixed effects, and an unstructured covariance matrix is used to model the within-patient errors. This
corresponds to xi = (1, yi0, gi)′ in terms of model (1). SAS PROC MIXED yields the same result as our analytic formulae
if a more stringent convergence criterion (CONVG= 1E-10 option) than the default is used. The KR variance estimate
is smaller than the delta variance, but slightly larger than the asymptotic variance. The p-value for testing the treatment
effect at week 6 is 0.0132 based on the KR variance estimate.
Table 1 also reports the result from the constrained longitudinal data analysis (cLDA), in which the baseline outcome is
treated as a response variable instead of a covariate, and constrained to have equal mean across treatment groups [21, 22].
For monotone missing pattern, the REML estimate and the associated variance estimate can be derived using essentially
the same technique described in Sections 2.1 and 2.3, and the details are omitted here. The REML estimates are in fact
identical, and the corresponding KR variance estimates are very close in MMRM and cLDA. This is consistent with the
simulation result reported in [22]. The cLDA is useful if there is a non-negligible amount of missing data at baseline.
However, for monotone missing data, the MMRM is generally preferred since there is no need to assume that yi0’s are
normally distributed and that the baseline means are equal across treatment groups in MMRM.
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3. Power and sample size formulae for MMRM
3.1. Power and sample size formulae
Throughout Section 3, we assume the hypothesis of interest is to test the treatment effect at the last visit. Let γg be
the proportion of subjects randomized to group g, πgt the retention rate at visit t in group g, and π¯t =∑1g=0 γgπgt
the pooled retention rate at visit t. Then ngt = nγgπgt. In the variance expression (8), xbi’s are assumed to be fixed
in the analysis, but unknown at the design stage. We will replace Vxj ’s in equation (8) by their expected values. Suppose
the covariates are balanced between two arms. We don’t require the covariates to be continuous, or follow a specific
distribution in randomized trials. Let q∗ be the dimension of xbi, q = q∗ + 2 and ̟pit =
∑1
g=0(γgπgt)
−1
. It is easy to
show that n0tn1t(nt − q∗ − 1)/(ntq∗)∆′tS−1xt ∆t approximately follows a F distribution with q∗ and nt − q∗ − 1 d.f. (this
holds exactly if xbi is normally distributed). We have
E(∆′tS−1xt ∆t) ≈
̟pit
n
̟δt(n) and E(Vxt) ≈
̟xt(n)
n
. (11)
where ̟δt(n) = q∗/(nπ¯t − q − 1) and ̟xt(n) = ̟pit [1 +̟δt(n)] are functions of n.
If we use var
E
(βj), then ωjtσ2t = σ2j /(nj − q). The (expected) variance of τˆp is ̟τ (n)/n, where
̟τ (n) =
p∑
j=1
l2pjσ
2
j̟xj(n) +
p∑
j=2
l2pjσ
2
j
∑j−1
t=1 (̟xj (n)−̟xt(n))
nπ¯j − q .
The power of the Wald test at a two-sided significance level of α is given by
P = Pr(| τˆp√
v̂arkr(τˆp)
| ≥ tf,1−α
2
) =Pr(t(f,
√
nλ) ≥ tf,1−α
2
)+
Pr(t(f,
√
nλ) ≤ −tf,1−α
2
) ≈ Pr(t(f,√n|λ|) ≥ tf,1−α
2
),
(12)
where v̂arkr(τˆp) is the (q, q) entry of v̂arkr(αˆp) defined in equation (10), λ = τp/
√
̟τ (n), t(f, ν) is distributed as a
non-central t distribution with f d.f. and non-central parameter ν, and tf,p is the p-th percentile of tf . To simplify the
calculation, we approximate the power by
P = Pr(τˆ∗p ≥ tf,1−α2 −
√
nλ) + Pr(τˆ∗p ≤ −tf,1−α2 −
√
nλ) ≈ Pr(τˆ∗p ≤
√
n|λ| − tf,1−α
2
), (13)
where τˆ∗p = (τˆp − τp)/
√
v̂arkr(τˆp) approximately follows a t distribution with f d.f., and
√
nλ =
τp√
v̂arkr(τˆp)
≈ τp√
n−1̟τ (n)
.
For a scalar fixed effect, Kenward and Roger [10] used the Satterthwaite-type d.f., which is a random variable (could be
larger than n1 − q), and difficult to evaluate at the design stage. We approximate f by
f(n) = (n1 − q)fo = (nπ¯1 − q)fo,
where
fo =
(
∑p
j=1 l
2
pjσ
2
j )̟x1∑p
j=1 l
2
pjσ
2
j̟xj
≈ (
∑p
j=1 l
2
pjσ
2
j )̟pi1∑p
j=1 l
2
pjσ
2
j̟pij
can be roughly interpreted as the fraction of observed information among subjects retained at visit 1.
Statist. Med. 2015, 00 1–14 Copyright c© 2015 John Wiley & Sons, Ltd. www.sim.org 7
Prepared using simauth.cls
Statistics
in Medicine Y. Tang
There is no closed-form solution for the sample size needed to achieve a desired power P . We propose a two-step
procedure to approximate the required size. Inverting equation (13) yields
ntar = (tf,1−α
2
+ tf,P)
2̟τ (n)
δ2p
=
(tf,1−α
2
+ tf,P)
2
λ2
. (14)
In large samples, we can approximate tf,p by the pth percentile zp of N(0, 1), and approximate ̟τ (n) by ̟∗τ [1 +
q∗(
∑p
j=1 bj/π¯j)/n], where ̟∗τ =
∑p
j=1 l
2
pjσ
2
j̟pij and bj = l2pjσ2j̟pij/̟∗τ . In step 1, we find the sample size based on
the normal approximation
nl = (z1−α
2
+ zP)
2̟
∗
τ
δ2p
+ q∗
p∑
j=1
bj
π¯j
≈ (z1−α
2
+ zP)
2̟
∗
τ
δ2p
+
q∗
π¯p
, (15)
and it generally provides a sharp lower bound on the required size. If the retention rate is low (e.g. π¯p < 0.5), we use
the first equality in equation (15). In the implementation, we round nl up to the nearest integer. In step 2, we use the
approximation
nu = (tf(nl),1−α2 + tf(nl),P)
2̟τ (nl)
δ2p
, (16)
and it usually provides a very good estimate of the required size. We may approximate nu by
n∗u ≈ (tf(nl),1−α2 + tf(nl),P)2
̟∗τ
δ2p
+ q∗
p∑
j=1
bj
π¯j
≈ (tf(nl),1−α2 + tf(nl),P)2
̟∗τ
δ2p
+
q∗
π¯p
. (17)
We recommend using equation (16) or equation (17) to estimate the sample size, and using equation (12) to evaluate the
nominal power at a given sample size since equation (12) is more accurate than equation (13) when f is extremely small
(e.g. f < 12). If the nominal power at nu or n∗u is not close to the targeted power, one may increase or decrease the sample
size to achieve the desired power.
We also try a slight variation of the proposed size estimation procedure by increasing nl defined in equation (15) by 2,
but all other steps remain the same. More details are provided in simulation 1 reported in Section 3.2.1 below.
3.2. Numerical examples
3.2.1. Simulation 1. In an antidepressant trial analyzed in Section 2.4, the active treatment is significantly better
than placebo in reducing depression. It might be of interest to design a new study to assess the effect of a similar
compound on HAMD17. Suppose p = 4, yi0
i.i.d∼ N(17.9, 5.52), µi1 = 3.3 + 0.72y0 + 0.1gi, µi2 = 2.7 + 0.69y0 − 1.5gi,
µi3 = 2.9 + 0.61y0 − 2.3gi, µi4 = 1 + 0.67y0 + τ4gi,
yi1
yi2
yi3
yi4
 ∼ N4


µi1
µi2
µi3
µi4
 ,

19.68 16.45 15.39 16.36
16.45 34 25.34 26.13
15.39 25.34 38.44 33.91
16.36 26.13 33.91 45.28

 ,
and the retention rate is (π01, . . . , π04) = (1, 0.92, 0.86, 0.74) and (π11, . . . , π14) = (1, 0.93, 0.87, 0.76). These parameters
are specified based roughly on the MMRM analysis of the antidepressant trial. Note that the sample size depends on
the retention rates, the treatment effect τ4 at the last visit, and Σ. Other parameters are specified in order to simulate
the data. For the purpose of illustration, we set τ4 = −4, −8 or −12, and three alternative covariance structures are also
considered: 1) a compound symmetry (CS) structure: Σkk = 45 and Σkj = 15 if k 6= j; 2) an autoregressive (AR(1))
structure Σjk = 45× 0.8|j−k|; 3) a Toeplitz structure Σjk = 40− 6|j − k|. For CS and AR(1) structures, the analytic
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Table 2: Calculated sample sizes and simulated power based on 10, 000 replications for testing H0 : τ4 = 0
in simulation 1: a The sample size is evaluated using equation (16). The size estimates from equations (15)
and (17) are presented for the purpose of comparison; b The difference in sample size between two arms
is 0 for even n and 1 for odd n; c The nominal power is evaluated as Pr(t(f(n),
√
n|τ4|/
√
̟τ (nl)) ≥
tf(n),0.975) based on equation (12). The difference in nominal power estimated by equation (12) and
equation (13) is < 0.2% in all cases.
true covariance estimated sample sizea total power (%)
structure τ4 nl n∗u nu size n b nominalc simulated
1: Unstructured −12 17 19.4 20.4 21 91.86 91.48
−8 36 38.1 38.6 39 90.49 89.99
−4 139 140.8 141.0 142 90.22 90.47
2: CS −12 19 21.1 22.7 23 91.36 90.84
−8 40 41.8 42.7 43 90.36 89.74
−4 153 154.8 155.5 156 90.11 90.22
3: AR(1) −12 17 19.6 20.7 21 91.53 91.10
−8 36 38.4 39.0 39 90.24 89.75
−4 140 141.8 142.1 143 90.21 90.87
4: Toeplitz −12 15 17.6 18.7 19 91.81 91.86
−8 32 33.9 34.3 35 90.81 90.31
−4 122 123.7 123.9 124 90.04 89.71
expressions for the LDL decomposition provided in the appendix can be used in the calculation.
We calculate the sample size necessary to achieve 90% power at a two-sided significance level of α = 0.05 using
equation (16). In each case, 10000 datasets are simulated and analyzed using model (1) and KR variance estimate. There
is about 95% chance that the simulated power lies within 0.6% (standard error ≈√0.9 ∗ 0.1/10000 = 0.3%) of the true
power. The result is summarized in Table 2. The difference between the simulated and nominal power is < 1% in all cases.
Empirical evidence indicates that the normal approximation based on equation (15) usually underestimates the sample
size by at least 2. We try a slight variation of the sample size estimation procedure by increasing nl by 2 (all other steps
remain the same). This modification makes a difference mainly in small samples (i.e. τ4 = −12) in that the sample size
estimate is reduced by 1. We still recommend the procedure described in Section 3.1 since it is generally desirable to use
a conservative size estimate.
3.2.2. Simulation 2. This simulation illustrates that the power and sample size depend on the number of covariates. The
covariates consist of the baseline outcome yi0, treatment status gi and a categorical prognostic factor A with three levels.
Suppose the status of the prognostic factor is Ai for subject i, yi0 i.i.d∼ N(ηAi + 17.9, 5.52), and
yi1
yi2
yi3
yi4
 ∼ N4


η
Ai
+ µi1
η
Ai
+ µi2
η
Ai
+ µi3
η
Ai
+ µi4
 ,Σ
 ,
where η1 = 0, η2 = −0.5, η3 = 0.5, and µij ’s are defined in simulation 1. We assume that the effect of the prognostic
factor is constant over time, and that each subject is in level 1, 2 and 3 of the prognostic factor with probability 0.3, 0.4,
and 0.3 respectively. Other assumptions are the same as that in simulation 1. In the MMRM analysis, the fixed effects
include visit, yi0 × visit, A× visit and treatment× visit interactions.
The result is displayed in Table 3. The required size in simulation 2 is larger than that in simulation 1 under the
same assumption on the treatment effect and residual covariance matrix Σ due to the increase in the number of baseline
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Table 3: Calculated sample sizes and simulated power based on 10, 000 replications for testing H0 : τ4 = 0
in simulation 2: a The sample size is evaluated using equation (16). The size estimates from equations (15)
and (17) are presented for the purpose of comparison; b The difference in sample size between two arms
is 0 for even n and 1 for odd n; c The nominal power is evaluated as Pr(t(f(n),
√
n|τ4|/
√
̟τ (nl)) ≥
tf(n),0.975) based on equation (12).
true covariance estimated sample size a total power (%)
structure τ4 nl n∗u nu size n b nominalc simulated
1: Unstructured −12 20 21.9 23.5 24 91.51 91.67
−8 39 40.7 41.2 42 90.70 90.91
−4 142 143.4 143.4 144 90.13 89.65
2: CS −12 21 23.8 27.1 28 92.30 92.97
−8 42 44.5 45.9 46 90.27 90.01
−4 155 157.5 158.2 159 90.17 89.99
3: AR(1) −12 20 22.0 23.9 24 91.09 91.12
−8 39 41.0 41.7 42 90.42 90.67
−4 143 144.4 144.5 145 90.12 89.74
4: Toeplitz −12 18 20.0 21.9 22 91.31 91.52
−8 35 36.4 36.9 37 90.24 89.96
−4 125 126.4 126.3 127 90.17 90.52
covariates. The difference between the simulated and nominal power is < 1% in all cases. Overall, the sample size is
underestimated by the normal approximation approach given in equation (15) especially at τ4 = −12, and the proposed
two-step sample size calculation method performs well when the d.f. in equation (16) is larger than f(nl) ≥ 12.
3.2.3. Simulation 3. So far, we assume the data are normally distributed. The third simulation is conducted to assess
the performance of the proposed method for non-normal data in small to moderate samples (τ4 = −8 or −12). The
data are simulated from the multivariate skew-normal distribution [23] and multivariate t distribution. For the purpose
of comparison, we set the covariance matrix of (yi1, . . . , yi4) and the treatment effect at each visit to be identical to that in
simulation 1. The nominal power and sample size estimates will be same as that in simulation 1.
In the multivariate t distribution, we generate the data as yij = µij + ǫij/
√
ui/d, where ui
i.i.d.∼ χ2d follows a chi-square
distribution with d d.f., and (ǫi1, . . . , ǫi4)′ is normally distributed with zero mean vector and covariance matrix d−2d Σ. The
covariance matrix of (yi1, . . . , yi4) is Σ. We set d = 6 or 10. The skewness of yij is 0. The (excess) kurtosis of yij is
6/(d− 4) = 3 at d = 6 and 1 at d = 10.
The skew-normal distribution [23] can be used to model data that are mildly to moderately skewed. Let R = D−1ΣD−1
be the correlation matrix corresponding to Σ, and R2 = (1 − κ2)−1[aR− b1p1′p], where κ is a prespecified scalar
value in the interval (−1, 1), a = 1− 2κ2/π, b = (1− 2/π)κ2, and D = diag(Σ11, . . . ,Σpp). The data are generated as
yij = µij +
√
Σjj/a ǫij , where ǫij = κei +
√
1− κ2 ǫ˜ij , ei i.i.d.∼ N(0, 1), and (ǫ˜i1, . . . , ǫ˜ip)′ ∼ Np(0, R2). The covariance
matrix of (yi1, . . . , yi4)′ is Σ. The marginal distribution of ǫ˜ij isN(0, 1), and the skewness of ǫij (yij has the same skewness
as ǫij ) ranges from −0.995 to 0.995 as κ changes from −1 to 1. We set κ = 0.8 and 0.9. No result is produced for the CS
covariance structure at κ = 0.9 since the corresponding R2 is not positive definite.
The result is presented in Table 4. In general, the type I error is close to the nominal 5% level except in few cases under
the t distribution with 6 d.f., where the t test with KR adjusted variance provides slightly conservative control of the type
I error. The performance on the power estimate is almost as good as that under the normality assumption in simulation
1. The simulated power is within 1.2% of the nominal power in all cases. Additional simulation (results not shown) is
conducted under the skew-normal distribution at κ = −0.8,−0.9 and ±0.95, and different covariance matrices may be
used to ensure that R2 is positive definite. All simulations indicate that the proposed power and sample size estimation
procedure is fairly robust to mild or moderate deviations from non-normality even when n = 20.
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Table 4: Calculated sample sizes and simulated power based on 10, 000 replications for testing H0 : τ4 = 0
under multivariate t and skew-normal distributions in simulation 3: a The sample size and nominal power
estimates are identical to that in simulation 1; b Type I error (Type1) is evaluated at τ4 = 0; c Simulated
power (SIM) is evaluated at τ4 = −8 and −12.
total nominal skew-normal distribution (%) multivariate t distribution (%)
true covariance sizea power a κ = 0.8 κ = 0.9 10 d.f. 6 d.f.
structure τ4 n (%) Type1b SIMc Type1 SIM Type1 SIM Type1 SIM
1: Unstructured −12 21 91.86 4.97 91.26 4.84 91.02 5.21 90.80 4.39 90.87
−8 39 90.49 5.05 90.07 5.10 90.32 4.97 89.52 4.83 90.25
2: CS −12 23 91.36 4.86 90.56 − − 5.09 90.30 4.72 90.18
−8 43 90.36 4.84 89.66 − − 5.28 89.63 5.06 89.82
3: AR(1) −12 21 91.53 4.89 90.91 4.99 90.72 5.13 90.54 4.35 90.45
−8 39 90.24 5.06 89.92 4.93 89.91 4.92 89.28 4.86 90.09
4: Toeplitz −12 19 91.81 5.24 90.80 4.93 90.88 4.91 91.07 5.11 91.13
−8 35 90.81 5.01 90.26 4.82 90.84 5.30 89.69 4.99 90.36
4. Discussion
We derive the closed-form REML estimator and compare several variance estimators for fixed effects in MMRM when the
missing data pattern is monotone. The bias in the ML and REML parameter estimators is assessed. For monotone missing
data, the MMRM yields the same treatment effect as the cLDA [22], but it makes less assumption on the distribution of
baseline outcomes. One referee raises concern over the terminology MMRM since there is no random effect in model (1).
We partially agree with the referee, but this terminology is commonly used in the pharmaceutical industry [1, 2, 3].
A two-step sample size determination procedure is proposed for the KR adjusted t test for comparing two treatments
in MMRM. Simulation demonstrates its good performance even in small samples. When the d.f. given in equation (16)
is f(nl) < 12, the power formula (12) still works reasonably well, but the required size can be overestimated. The main
reason is because the normal approximation approach generally underestimates the required size and hence the d.f., leading
to non-negligible inflation in tf,1−α/2 + tf,P and ̟τ (n) in small samples. When f(nl) < 12, we would recommend using
a numerical (e.g. bisection) method to find the size based on equation (12), which is the smallest integer at which the
power reaches the pre-specified level. Simulation indicates that the proposed method is quite robust to mild or moderate
deviations from non-normality. However, this robustness property may not hold under severe non-normality even for the
one sample t test [24]. It is always prudent to run a simulation study to verify the power and sample size estimate especially
when the data are highly non-normal or when the sample size is small. We assume balanced baselines across groups. If
the baselines are imbalanced, we may replace equation (11) by
E(∆′tS−1xt ∆t) ≈
̟δt(n)̟pit
n
+
D
nπ¯t − q − 1 and E(Vxt) =
̟xt(n)
n
+
D
nπ¯t − q − 1 ,
where µd is the difference in mean of xbi between two arms, Σx is the covariance matrix of xbi and D = µ′dΣ−1x µd.
In a companion paper, we investigate the power of treatment comparison in an unstratified randomized trial, and the
power for testing treatment effect and treatment by stratum interaction in a stratified trial using analysis of covariance
(ANCOVA). For the MMRM analysis of a stratified trial with h strata, we may replace equation (11) by
̟δt(n) =
q∗
nπ¯t − q − 1 and E(Vxt) ≈
̟xt(n)
n
=
̟pit [1 +̟δt(n)]
n
, (18)
where q∗ is the dimension of covariates excluding intercept, treatment status, and pre-stratification factors, (xi1 , . . . , xih−1)
are the indicator variables for strata, xi = (1, xi1 , . . . , xih−1 ,x′bi, gi)′ and q = q∗ + h+ 1. Equation (18) is derived by
Statist. Med. 2015, 00 1–14 Copyright c© 2015 John Wiley & Sons, Ltd. www.sim.org 11
Prepared using simauth.cls
Statistics
in Medicine Y. Tang
assuming constant treatment effect, treatment allocation ratio and retention rate across strata.
Simulation 2 indicates that including the correction term ̟δt in ̟xt in equations (12) and (13) and the last term in
equations (15) and (16) can greatly improve the accuracy of the power and sample size estimate when q∗ is large or n is
relatively small. Covariate selection is critical in small trials. In the power calculation, Σ = LΛL′ is the variance of the
outcome unexplained by the covariates. Inclusion of important covariates can reduce the residual variance Σ, and increase
the power of the analysis. However, if the covariates are unrelated or only weakly related to the outcome, both the precision
of the treatment effect estimate (by equation (11)) and the d.f. in the t test may decrease, resulting in reduced power.
It can be challenging to specify Σ at the design stage of a trial. One strategy is to assume a structured covariance matrix
that represents the best guess about the true covariance matrix to reduce the number of nuisance parameters in the sample
size calculation [12], but the data are still analyzed by model (1). Furthermore, blinded size reassessment procedure may
be used to re-estimate the variance parameters and adjust the size based on interim blinded data, in which the treatment
effect is generally small and thus ignored in estimating the variance parameters [25].
We assume monotone missing pattern in the power and sample size calculation. In practice, the trials generally contain
only a small amount of intermittent missing data. For example, in the anti-depressant trial analyzed in Section 2.4, only
one out of 172 subjects has intermittent missing values. In the presence of non-monotone missing data, sample size can
be calculated in a slightly conservative way by excluding subjects with intermittent missing data or by excluding data
collected after the first missing visit. One needs to adjust the retention rates before applying the power and sample size
formulae derived in section 3.1. If a large amount of intermittent missing data is expected, one may use simulation to find
the appropriate sample size. The above approach provides an upper size bound, and a lower size bound can be obtained
by pretending there are no intermittent missing data.
One limitation of the proposed method is that the data are assumed to be missing at random in the MMRM. Sensitivity
analyses under the nonignorable missingness have become increasingly popular in new drug applications [26, 20, 9].
Sample size formulae for such sensitivity analysis may be obtained by using the analytical expressions for the MI treatment
effect estimate and the associated variance derived in [19].
We have focused on the longitudinal continuous outcome. For other types of longitudinal outcomes (e.g. binary or
ordinal), one may use the methods described in [27, 28] to compute the sample size for the tests based on the generalized
estimating equations (GEE). However, these methods may not be suitable for small samples [29].
The analytic REML solution is useful in statistical computing. For example, we find the default REML estimation
algorithm used by SAS Proc mixed fails to converge in about 5% monotone datasets at n = 15 in a simulation, but
the REML estimate can be easily obtained using Lemma 1. For near-monotone datasets, the convergence of the REML
algorithm may be accelerated by using the REML estimate excluding subjects with intermittent missing data as the initial
parameter values. For non-monotone data, Liu [8] proposed a MEM algorithm to find the ML estimate. It is also possible
to develop a MEM algorithm for the REML estimation, and the details will be presented elsewhere.
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A. Appendix: technical details
Proof of Lemma 1: (a) Let Uk, Lk = U−1k , Λk and Σk = LkΛkL′k denote respectively the leading k × k submatrix
of U , L = U−1, Λ and Σ = LΛL′. Then Wi = I˜ri ⊗ xi, W ′iΣ−1ri Wi = (
∑ri
s=1 β˜
′
sβ˜s/σ
2
s)⊗ (x′ixi),
∑
iW
′
iΣ
−1
ri Wi =∑p
s=1[(β˜
′
sβ˜s)⊗ (X ′osXos/σ2s)], (L′ ⊗ Ip)(
∑
iW
′
iΣ
−1
ri Wi)(L⊗ Ip) = V −1w , where I˜k is formed by the first k row of Ip,
and β˜s = (−βs1, . . . ,−βss−1, 1, 0, . . . , 0)′. Thus (a) holds.
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(b) We can prove (b) by showing ∑i yiΣ−1ri yi =∑pj=1(σ−2j ∑njk=1 y2j), ∑i log |Σri | − log |∑iW ′iΣ−1ri Wi| =
∑p
j=1(nj − q) log(σ2j ),
∑n
i=1W
′
iΣ
−1
ri yio = (U
′ ⊗ Ip)
σ
−2
1
∑n1
i=1 x
′
iyi1
. . .
σ−2p
∑np
i=1 x
′
iyip
, and the last term of equation (2) equals
−∑pj=1[σ−2j (∑nji=1 x′iyij)′(X ′ojXoj)−1(∑nji=1 x′iyij)].
(c) Maximizing equation (5) yields (βˆj , σˆ2j,re)’s, andαj’s are evaluated at the REML estimator (βˆj , σˆ2j,re)’s. We can prove
θˆj,re = θˆj by using [
x′x x′z
z′x z′z
]−1
=
[
(x′x)−1 + ηVzη
′ −ηVz
−Vzη′ Vz
]
, (19)
where Vz = [z′(I − x(x′x)−1x′)z]−1, and η = (x′x)−1x′z.
(d) Let ~Y oj = (Y oj1 , . . . , Y oj,j−1) = ~YojU ′j−1. By equation (3), Y ojk ∼ N(Xojαk, σ2kInj ), and Y ojk ’s (k = 1, . . . , j − 1)
are independent. Lemma 1(e) holds since E(~Y ′ojQj ~Y oj) = (nj − q)Λj−1 and E(~Y ′ojQj ~Yoj ) = (nj − q)Σj−1.
Proof of equation (6): A little algebra shows that αˆk =
∑k−1
t=1 βˆktαˆt + αˆk, α˜k =
∑k−1
t=1 βktα˜t + α˜k, αˆk − α˜k =
dk + ek +
∑k−1
t=1 βkt(αˆt − α˜t), and
(αˆ1 − α˜1, . . . , αˆk − α˜k)′ = Lk(d1 + e1, . . . , dk + ek)′, (20)
where αˆ∗kt = (X ′okXok)
−1X ′okY okt , ζk = L
′
k−1(βˆk − βk), α˜k − αˆk = (X ′okXok)−1X ′ok ~Yok(βˆk − βk) =
(αˆ∗k1, . . . , αˆ
∗
kk−1)ζk, d1 = e1 = 0, dk =
∑k−1
t=1 (βˆkt − βkt)α˜t + (αˆk − α˜k) = (α˜1 − αˆ∗k1, . . . , α˜k−1 − αˆ∗kk−1)ζk
and ek =
∑k−1
t=1 (βˆkt − βkt)(αˆt − α˜t) = (d1 + e1, . . . , dk−1 + ek−1)ζk at k ≥ 2. Note that dk’s, ek’s and α˜k’s are
independent, var(dk) =
∑k−1
t=1 σ
2
tωktDkt, and E(dk) = E(ek) = 0. Thus cov(α˜, αˆ− α˜) = 0. Let ǫj = αˆj − α˜j and
ǫ = (ǫ′1, . . . , ǫ
′
p)
′
. By equation (20), we have var(ǫ) = (L⊗ Iq)Vde(L⊗ Iq)′ and var(α˜p − αˆp) =
∑p
j=2 l
2
pj(Vdj + Vej),
where Vde = diag(0, Vd2 + Ve2, . . . , Vdp + Vep).
Proof of equation (9): Let gj = σ2j l2pj and cj = E(gˆj)− gj . Then E(Φˆp)− Φp =
∑
j cj(X
′
ojXoj )
−1
. We evaluate cj using
the second-order Taylor series approximation
cj ≈ ∂gj
∂σ2j
E(σˆ2j − σ2j ) +
1
2
∂2gj
∂lj∂lj
E(lˆj − lj)2 = σ2j var(lpj)−
j − 1
nj − q σ
2
j l
2
pj ,
by noting E(lˆj − lj) = 0, E(lˆj − lj)(σˆ2j − σ2j ) = 0 and ∂2gj/∂σ2j∂σ2j = 0. Since ∂(lpj)/∂βk = lpk(l1j , . . . , lk−1,j)′ [it is 0
if j ≥ k] and (l1j , . . . , lk−1,j)var(βk)(l1j , . . . , lk−1,j)′ = ωkj , we have var(lpj) =
∑p
k=j+1 l
2
pkωkj and equation (9) holds.
Analytic expressions for LDL decomposition of CS and AR(1) covariance
For an AR(1) covariance matrix (Σjk = hρ|j−k|), the LDL decomposition satisfies ljk = ρ|j−k| if k ≤ j, ljk = 0 if j > k,
σ21 = h, and σ2k = h(1− ρ2) for k ≥ 2.
For a CS covariance matrix (Σjk = hρ if j 6= k, h if j = k), we have ljk = 1 if k = j, ρ1+(k−1)ρ if k < j, and 0 otherwise,
and σ21 = h, σ22 = h(1− ρ2), and σ2k = σ2k−1[1− ( ρ1+(k−2)ρ )2] for k ≥ 2.
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